TD Asset Management’s Pacific Biosciences PACB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-292,686
| Closed | -$536K | – | 1255 |
|
|
2024
Q4 | $536K | Hold |
292,686
| – | – | ﹤0.01% | 1179 |
|
|
2024
Q3 | $512K | Hold |
292,686
| – | – | ﹤0.01% | 1298 |
|
|
2024
Q2 | $401K | Sell |
292,686
-240,814
| -45% | -$330K | ﹤0.01% | 1299 |
|
|
2024
Q1 | $2M | Sell |
533,500
-127,800
| -19% | -$479K | ﹤0.01% | 1024 |
|
|
2023
Q4 | $6.49M | Sell |
661,300
-43,400
| -6% | -$426K | 0.01% | 695 |
|
|
2023
Q3 | $5.88M | Buy |
704,700
+285,343
| +68% | +$2.38M | 0.01% | 700 |
|
|
2023
Q2 | $5.58M | Buy |
419,357
+18,985
| +5% | +$253K | 0.01% | 714 |
|
|
2023
Q1 | $4.64M | Buy |
400,372
+33,794
| +9% | +$391K | 0.01% | 766 |
|
|
2022
Q4 | $3M | Buy |
366,578
+73,368
| +25% | +$600K | ﹤0.01% | 872 |
|
|
2022
Q3 | $1.64M | Buy |
293,210
+104,152
| +55% | +$583K | ﹤0.01% | 1064 |
|
|
2022
Q2 | $836K | Sell |
189,058
-79,600
| -30% | -$352K | ﹤0.01% | 1211 |
|
|
2022
Q1 | $2.45M | Buy |
268,658
+31,223
| +13% | +$284K | ﹤0.01% | 1025 |
|
|
2021
Q4 | $4.86M | Buy |
237,435
+4,666
| +2% | +$95.5K | ﹤0.01% | 878 |
|
|
2021
Q3 | $5.95M | Buy |
232,769
+4,217
| +2% | +$108K | 0.01% | 779 |
|
|
2021
Q2 | $7.35M | Buy |
228,552
+3,598
| +2% | +$116K | 0.01% | 732 |
|
|
2021
Q1 | $7.49M | Buy |
224,954
+30,227
| +16% | +$1.01M | 0.01% | 714 |
|
|
2020
Q4 | $5.05M | Buy |
194,727
+77,056
| +65% | +$2M | 0.01% | 787 |
|
|
2020
Q3 | $1.16M | Buy |
+117,671
| New | +$1.16M | ﹤0.01% | 1061 |
|